Firefly Supply

Firefly Bio is a biopharmaceutical company focused on developing a new class of therapeutics called Degrader-Antibody Conjugates (DACs). By combining the precise targeting of antibodies with the potent intracellular protein degradation capabilities of PROTACs, the company aims to treat cancer and other challenging diseases. Their platform is designed to deliver degraders specifically to diseased cells, overcoming the limitations of systemic protein degradation and expanding the reach of both ADCs and degraders. Firefly Bio emerged from incubation at Versant Ventures' Ridgeline Discovery Engine with significant seed and Series A funding.